← brief for 2026-09-04 · Slowing decline

Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy.

Key takeaways

This hospital record review compared two blood thinners in people with kidney failure on dialysis: warfarin type drugs, and low dose apixaban at 2.5 mg twice a day with blood level checks. Both are used to prevent stroke in an irregular heartbeat and to stop repeat blood clots. Outside the United States, apixaban is not approved for people on dialysis, so this fills a real gap. It compares groups of past patients, so it shows a link between drug choice and bleeding or clotting, not proof of cause.

Who did this work

Bartoli-Abdou JK (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Cohen AT (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Vernon L (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Collings V (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Chaichana U (Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.) · Moore N (Department of Pharmacy, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Jibril H (Institute of Pharmaceutical Science, King's College London, London, UK.) · Wei L (Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.) · Kumar N (Renal Department, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Breen KA (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.) · Doyle AJ (Department of Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, London, UK.)

Source

Paper · Europe PMC, CKD · 2026-09-04
https://doi.org/10.1002/bcp.70805